Lv5
1088 积分 2025-06-05 加入
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases
5个月前
已完结
Frontline Dara-CyBorD for AL amyloidosis: high response rates and cytogenetic insights from a real-world cohort
5个月前
已完结
Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone
6个月前
已完结
Van Oekelen O, Nath K, Mouhieddine TH, et al. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy. Blood . 2023;141(7):756-765
6个月前
已关闭
Belantamab mafodotin, lenalidomide and dexamethasone (BelaRd) in newly diagnosed intermediate-fit and frail myeloma
6个月前
已关闭
A High-Fiber Plant-Based Diet in Myeloma Precursor Disorders – Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model
6个月前
已完结
Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment
6个月前
已完结
Isatuximab: surface strike, deep response in AL amyloidosis
6个月前
已关闭
Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy
7个月前
已完结
Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy
7个月前
已关闭
皖公网安备34019202002308
